Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura

Transfusion

Volumn 55, Issue 1, 2015, Pages 18-24

  Wu, Nan ^a   Liu, Jia ^b   Yang, Shangbin ^a   Kellett, Eric T ^a   Cataland, Spero R ^a   Li, Hong ^b   Wu, Haifeng M ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYCLOSPORIN; PREDNISOLONE; PREDNISONE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE; ADAM PROTEIN; ADAMTS13 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEATH; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE EXACERBATION; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; PLASMAPHERESIS; PROGNOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; TREATMENT RESPONSE; ADVERSE EFFECTS; BLOOD; DEFICIENCY; ENZYME ASSAY; FOLLOW UP; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SENSITIVITY AND SPECIFICITY;

ADAM PROTEINS; ADULT; AGED; CLINICAL ENZYME TESTS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PREDNISONE; PROGNOSIS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84920828759     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.12762     Document Type: Article

References (31)

1. George JN,. Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006; 354: 1927-1935.
2. Sadler JE, Moake JL, Miyata T, et al. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2004; 407-423.
3. Scully M, Goodship T,. How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome. Br J Haematol 2014; 164: 759-766.
4. Wong EK, Goodship TH, Kavanagh D,. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013; 56: 199-212.
5. Cataland SR, Wu HM,. Diagnosis and management of complement mediated thrombotic microangiopathies. Blood Rev 2014; 28: 67-74.
6. Cataland SR, Holers VM, Geyer S, et al. Biomarkers of the alternative pathway and terminal complement activity at presentation confirms the clinical diagnosis of aHUS and differentiates aHUS from TTP. Blood 2014 April 2 [Epub ahead of print].
7. Cataland SR, Wu HM,. How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome. Blood 2014; 123: 2478-2484.
8. Tsai HM, Lian EC,. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998; 339: 1585-1594.
9. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998; 339: 1578-1584.
10. Sadler JE,. Biochemistry and genetics of von Willebrand factor. Ann Rev Biochem 1998; 67: 395-424.
11. Levy GG, Motto DG, Ginsburg D,. ADAMTS13 turns 3. Blood 2005; 106: 11-17.
12. Lotta LA, Wu HM, Musallam KM, et al. The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura. Blood Rev 2013; 27: 71-76.
13. Peyvandi F, Palla R, Lotta LA, et al. ADAMTS-13 assays in thrombotic thrombocytopenic purpura. J Thromb Haemost 2010; 8: 631-640.
14. Mannucci PM, Peyvandi F,. TTP and ADAMTS13: when is testing appropriate? Hematology Am Soc Hematol Educ Program 2007; 121-126.
15. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991; 325: 393-397.
16. Sarode R, Bandarenko N, Brecher ME, et al. Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research. J Clin Apher 2014; 29: 148-167.
17. Zheng XL, Kaufman RM, Goodnough LT, et al. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood 2004; 103: 4043-4049.
18. Bohm M, Betz C, Miesbach W, et al. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine. Br J Haematol 2005; 129: 644-652.
19. Jin M, Cataland SR, Bissell M, et al. A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry. J Thromb Haemost 2006; 4: 333-338.
20. Jin M, Casper TC, Cataland SR, et al. Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse. Br J Haematol 2008; 141: 651-658.
21. Lotta LA, Wu HM, Mackie IJ, et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood 2012; 120: 440-448.
22. Cataland SR, Yang S, Wu HM,. The use of ADAMTS13 activity, platelet count, and serum creatinine to differentiate acquired thrombotic thrombocytopenic purpura from other thrombotic microangiopathies. Br J Haematol 2012; 157: 501-503.
23. Coppo P, Bengoufa D, Veyradier A, et al. Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement. Medicine (Baltimore) 2004; 83: 233-244.
24. Coppo P, Schwarzinger M, Buffet M, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PloS ONE 2010; 5: e10208.
25. Kremer Hovinga JA, Vesely SK, Terrell DR, et al. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood 2010; 115: 1500-1511; quiz 1662.
26. Raife T, Atkinson B, Montgomery R, et al. Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion 2004; 44: 146-150.
27. Bentley MJ, Wilson AR, Rodgers GM,. Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort. Vox Sang 2013; 105: 313-318.
28. Cataland SR, Wu HM,. Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura. Expert Opin Pharmacother 2007; 8: 437-444.
29. Muia J, Gao W, Haberichter SL, et al. An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura. J Thromb Haemost 2013; 11: 1511-1518.
30. Liu C, Kallogjeri D, Dynis M, et al. Platelet recovery rate during plasma exchange predicts early and late responses in patients with thrombotic thrombocytopenic purpura. Transfusion 2013; 53: 1096-1107.
31. Tsai HM, Li A, Rock G,. Inhibitors of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura. Clin Lab 2001; 47: 387-392.